600011 Disclosed is a the use of : (i) a potassium channel opener or agonist or adenosine receptor agonist for example Adenosine and (ii) a local anaesthetic for example the Class 1 B antiarrhythmic agent Lignocaine and (iii) an opioid for example [D-Pen2,5]enkaphalin (DPDPE), in the preparation of a medicament for reducing damage to a postconditioned cell, tissue or organ following ischemia or trauma or during ischemia or reperfusion. Postconditioning is a particular therapy where there is rapid intermittent interruptions of blood flow in the early phase of reperfusion.
